News | April 25, 2025
Briefs: Ami Organics and Panacea Biotec
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
The grant is designated for the research and development of Pyronaridine
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The Issue opened on June 18, 2024 and closed on June 21, 2024
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Ami Organics has reported total income of Rs. 226.30 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
